The second vice president of Congress, Ana Pastor, announced yesterday that it would be necessary to address the complexity of personalized precision medicine (PPM) through a subcommittee in Congress. According to the vice president, it is necessary to advance in a national MPP strategy, and she was interested in knowing the details of the national strategy to “analyze and promote it.”
Pastor affirmed that “to be at the forefront of health you have to listen to the experts” and thanked the experts in law and genome, genomics, digital health and pharmacogenomics for having conveyed their conclusions to members of the health commission.
Ana Pastor highlighted the need to have in-depth and authoritative information because parliamentarians “cannot be experts in everything.” She in this regard she mentioned to the Congressional Office of Science and Technology which informs parliamentarians about complex issues in a succinct way, although its documents are reduced to a few topics already decided in advance. Pastor concluded his intervention by stating that the question is to see “how these advances reach the patient” in relation to personalized precision medicine.
RELATED
First-hand information for parliamentarians
The opening of the meeting “MPP, medicine of the present or medicine of the future?” Promoted by the Roche Institute Foundation (IR), it included the president of the health commission, Rosa Romero, and the vice president of the IR Foundation, Federico Plaza, in the Clara Campoamor Room of the Congress of Deputies.
Parliamentarians, speakers and organizers participating and attending the meeting for members of the Health Commission held at the Congress.
rosemary rose thanked the initiative addressed to the members of the health commission present in the room, including the spokespersons for the Socialist Group, Grupo Popular and Grupo Vox, together with other members of the commission present.
Romero highlighted the intense activity of the health commission, the work of its members and thanked the invited speakers for providing “first-hand” information with this meeting, on something as relevant as precision medicine and its complexity.
The context of customizing
The preliminary conferences of the invited speakers made it possible to remember that medicine needs personalization, both to be more effective and to avoid adverse effects. Between 10 and 20% of patients in a hospital have some iatrogenic effect.
The Pharmacogenomics Working Party identified in 2015 that 34% of approved drugs had an associated biomarker. Currently, in oncohematology biomarkers are present between 80 and 90% of new drugs and indications.
Biomarker Portfolio
Experts agree that it is necessary to promote a portfolio of biomarkers while ensuring that the circuit for their determination is developed, including geneticists. It was also mentioned that the CISNS should bring order and facilitate a regulatory mechanism that allows equity in the use of biomarkers.
But it is not something new but widely requested by cancer societies, research groups and scientific entities. SEOM has had different meetings with the DG of Pharmacy in relation to a portfolio of biomarkers within the SNS.
And it is that without facilitating or extending the use of biomarkers, personalized precision medicine cannot be used for the benefit of the patient, its efficacy and safety results.
The health spokespersons, Ana Prieto (socialist group), Elvira Velasco (Popular group) and Juan Luis Steegmann (Vox group) they moved their positions and they were in favor of continuing to promote the MPP.
